Press "Enter" to skip to content

EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC) – PRNewswire

admin 0

EpicentRx Announces Publication of Its Positive Phase 2 3rd Line SCLC Results With RRx-001 Plus a Platinum Doublet in the British Journal of Cancer (BJC)  PRNewswire

LA JOLLA, Calif., June 25, 2019 /PRNewswire/ — EpicentRx Inc., a clinical-stage immuno-oncology company with two platforms developed to prime and activate …

“colorectal cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *